• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    2/1/24 4:02:29 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email
    SC 13G/A 1 ea192665-13ga2slager_pluri.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    PLURI INC.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    72942G 104

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐  Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 2 of 9 Pages

     

    1.

    Names of Reporting Persons

    Regals Capital Management LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    2,041,939

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    2,041,939

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,041,939

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.87%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 3 of 9 Pages

     

    1.

    Names of Reporting Persons

    Regals Fund LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    2,041,939

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    2,041,939

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,041,939

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.87%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 4 of 9 Pages

     

    1.

    Names of Reporting Persons

    David M. Slager

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Dutch

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    770,160

     

    6.

    Shared Voting Power

     

    2,041,939

     

    7.

    Sole Dispositive Power

     

    770,160

     

    8.

    Shared Dispositive Power

     

    2,041,939

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,812,099

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.70%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 5 of 9 Pages

     

    This Amendment No. 2 is filed with respect to the shares of Common Stock of the Issuer (as defined below) beneficially owned by the Reporting Persons (as defined below) as of December 31, 2023, and amends and reinstates the initial Schedule 13G filed by the Reporting Persons on January 26, 2022 as previously amended.

     

    Item 1(a).Name of Issuer

     

    Pluri Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices

     

    MATAM Advanced Technology Park, Building No. 5 Haifa, Israel 3508409.

     

    Item 2(a).Name of Person Filing

     

    This Schedule is filed on behalf of each of the following Reporting Persons:

     

    (1) Regals Capital Management LP (“Regals Management”)

     

    (2) Regals Fund LP (“Regals Fund”)

     

    (3) David M. Slager (“Mr. Slager”)

     

    Item 2(b).Address of Principal Business Offices or, if None, Residence

     

    The address of each Reporting Person is:

     

    c/o Regals Capital Management LP
    152 West 57th Street, 9th Floor
    New York, NY 10019

     

    Item 2(c).Citizenship

     

    Each of Regals Management and Regals Fund is a Delaware limited partnership.

     

    Mr. Slager is a citizen of The Netherlands.

     

    Item 2(d).Title of Class of Securities

     

    Common Stock.

     

    Item 2(e).CUSIP Number

     

    72942G 104

     

    Item 3.If the statement is being filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the filing person is a:

     

    Not Applicable

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 6 of 9 Pages

     

    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
       
    (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________________________________________________________

     

    Item 4. Ownership

     

    (a)Amount beneficially owned:

     

    As of the date hereof, Regals Fund directly owned (a) 1,555,939 shares of Common Stock and (b) warrants exercisable for 486,000 of Common Stock (“Warrant Shares”). Regals Management, as the investment manager of Regals Fund, may be deemed to beneficially own the shares of Common Stock owned directly by Regals Fund. Mr. Slager, as the managing member of the general partner of Regals Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Regals Management, in addition to the 770,160 shares of Common Stock he owns directly.

     

    (b)Percent of class:

     

    The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 41,480,172 shares of Common Stock outstanding as of November 13, 2023, as reported in the issuer’s Form 10-Q filed with the Securities and Exchange Commission plus the 486,000 Warrant Shares. As of the date hereof, each of Regals Fund and Regals Management may be deemed to have beneficially owned approximately 4.87% of the shares of Common Stock outstanding and Mr. Slager may be deemed to beneficially have owned approximately 6.70% of the shares of Common Stock outstanding.

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Cover Pages Items 5-9

     

    (ii)Shared power to vote or to direct the vote:

     

    See Cover Pages Items 5-9

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 7 of 9 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10.Certification

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 8 of 9 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each Reporting Person certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 1, 2024 Regals Capital Management LP
      By: Regals Capital Holdings LLC, its general partner
       
      /s/ David M. Slager
      Name:  David M. Slager
      Title: Managing Member
       
    Dated: February 1, 2024 Regals Fund LP
      By: Regals Fund GP LLC, its general partner
       
      /s/ David M. Slager
      Name: David M. Slager
      Title: Managing Member
       
    Dated: February 1, 2024 David M. Slager
       
      /s/ David M. Slager
      Name: David M. Slager

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 9 of 9 Pages

     

    EXHIBIT INDEX

     

    Exhibit   Description
         
    99.1   Agreement of Joint Filing. (Filed herewith)

     

     

     

     

     

     

     

     

    Get the next $PLUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

      Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

      5/15/25 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DarioHealth Announces CFO Transition

      NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

      4/21/25 8:30:00 AM ET
      $BNRG
      $DRIO
      $PLUR
      Building Products
      Industrials
      Medical/Dental Instruments
      Health Care
    • Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

      Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based cell therapies for solid cancersPluri's MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, "off-the-shelf" therapy for cancer patientsPluri's MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 billion in 2025In addition to MAIT cells, Pluri's platform also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), further broadening the scope of potential immune cell ther

      4/10/25 8:30:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/13/24 4:34:49 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/1/24 4:02:29 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      9/15/23 4:00:03 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pluri Inc.

      10-Q - Pluri Inc. (0001158780) (Filer)

      5/13/25 4:03:23 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Other Events

      8-K - Pluri Inc. (0001158780) (Filer)

      5/8/25 8:30:07 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Shareholder Director Nominations

      8-K - Pluri Inc. (0001158780) (Filer)

      4/29/25 4:00:31 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

      Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

      11/11/24 6:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shemesh-Rasmussen Maital was granted 11,173 shares, increasing direct ownership by 154% to 18,445 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:19 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Levi Rami Avraham was granted 11,173 shares, increasing direct ownership by 156% to 18,314 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:22 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Zalts Liat was granted 67,857 shares, increasing direct ownership by 319% to 89,107 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:17 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

      HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

      3/6/24 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

      HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

      7/13/23 2:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care